Clinical Trials Directory

Trials / Completed

CompletedNCT02918630

E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
7 (actual)
Sponsor
The University of Texas Health Science Center, Houston · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess if access to an electronic nicotine delivery device, or e-cigarette, in addition to nicotine patch (21 mg) can help reduce cigarette smoking among individuals diagnosed with schizophrenia compared to nicotine patch alone.

Conditions

Interventions

TypeNameDescription
DRUGNicotine PatchParticipants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
DRUGE-cigaretteThe e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).

Timeline

Start date
2016-10-01
Primary completion
2017-08-01
Completion
2017-08-01
First posted
2016-09-29
Last updated
2018-07-05
Results posted
2018-07-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02918630. Inclusion in this directory is not an endorsement.

E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia (NCT02918630) · Clinical Trials Directory